English, Article edition: Effectiveness of Eletriptan in Reducing Time Loss Caused by Migraine Attacks Nicholas E.J. Wells; Timothy J. Steiner

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118739
Physical Description
  • article
Language
  • English

Edition details

Title
  • Effectiveness of Eletriptan in Reducing Time Loss Caused by Migraine Attacks
Author
  • Nicholas E.J. Wells
  • Timothy J. Steiner
Physical Description
  • article
Notes
  • Background: The growing literature on the economics of migraine and its treatment generally indicates that the direct healthcare costs of managing the disorder are relatively low compared with the personal and societal burdens resulting from the disruption to normal functioning caused by migraine attacks. Objective: To investigate the effectiveness of eletriptan, a new selective serotonin (5-hydroxytryptamine; 5-HT) 5-HTIB/​ID agonist, in reducing both the patient-focused burden of migraine and the amount of work time foregone during a single attack. Design: In a phase III, multinational, randomised clinical trial, 692 patients treated a migraine attack with eletriptan 40mg or 80mg, or placebo. Patients responded to a questionnaire seeking information concerning the amount of time lost from usual activities during the attack. Time loss assessments were made 24 hours after the last dose taken and recorded in a diary. Main outcome measures and results: Patients receiving either dose of the active compound were unable to perform their usual activities for a median period of 4 hours compared with 9 hours experienced by those taking placebo. This difference was highly statistically significant (p < 0.001). The time saving associated with eletriptan usage reflected the differences in efficacy findings in the clinical component of the study. Conclusion: In this placebo-controlled trial, eletriptan produced a significant reduction in the loss of usual functioning time associated with a migraine attack. This gain clearly represents a substantial benefit to patients with migraine irrespective of how it might most appropriately be valued in monetary terms. Further methodological progress in this area is warranted.
  • Antimigraines, Cost analysis, Eletriptan, Migraine, Pharmacoeconomics, Research and development, Serotonin 1D receptor agonists
  • RePEc:wkh:phecon:v:18:y:2000:i:6:p:557-566
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment